<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151365">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129609</url>
  </required_header>
  <id_info>
    <org_study_id>Investigational Plan #119</org_study_id>
    <nct_id>NCT01129609</nct_id>
  </id_info>
  <brief_title>Talent Converter Post-Approval Study</brief_title>
  <official_title>Talent Converter Post-Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary endpoint is successful secondary endovascular treatment with the Talent
      Converter stent graft of subjects having received prior endovascular repair of infrarenal
      abdominal aortic or aortoiliac aneurysms using the Talent or AneuRx Bifurcated Stent Grafts,
      in which there is inadequate proximal fixation, seal, overlapping of modular components or
      unattainable contralateral limb cannulation.

      Treatment success is defined as a composite of successful vessel access, successful
      insertion of the delivery system, successful deployment of the Converter stent graft at the
      intended treatment site and absence of Type I endoleak at the 1 month follow-up visit.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Successful vessel access, successful insertion of the delivery system, successful deployment of the Converter stent graft at the intended treatment site and absence of Type I endoleak at the 1 month follow-up visit.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Abdominal Aortic Aneurysms</condition>
  <arm_group>
    <arm_group_label>All Enrolled Subjects</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System</intervention_name>
    <description>All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft</description>
    <arm_group_label>All Enrolled Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who are treated with the Talent Converter Stent Graft according to the
        indications for use
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects in whom a vessel access procedure was/will be performed with the attempted
             introduction of the Talent Converter Stent Graft for use according to the indications
             for use in the Instructions for Use (IFU) 0-365 days prior to enrollment.

          2. Subjects who are able to understand the nature of the study and give voluntary
             informed consent.

          3. Subjects who are available for follow-up visits.

          4. Subjects 18 years of age or older.

        Exclusion Criteria:

          1. Subjects in whom an attempted treatment was/will be performed with the Talent
             Converter Stent Graft other than (i.e., primary AUI) as a secondary endovascular
             intervention for patients having received prior endovascular repair with either a
             Talent or AneuRx bifurcated stent graft.

          2. Subjects in whom an attempted treatment was/will be performed with the Talent
             Converter Stent Graft as a secondary endovascular intervention for patients having
             received prior endovascular repair with a bifurcated stent graft other than (i.e.,
             Cook Zenith or Gore Excluder) a Talent or AneuRx bifurcated stent graft.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>April 29, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-approval observation of patients being treated according to the indications for use for the Talent Converter Stent Graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
